Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC
Clinical trial NCT03562637 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03562637
- Sponsor
- OBI Pharma, Inc
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-12-05
- Primary completion
- 2025-12-30
- Enrollment
- 575
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.